Clinical trial
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade…
NCT01891344 · pharmaand GmbH, Industry · Completed
Key facts
| NCT number | NCT01891344 |
|---|---|
| Title | A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) |
| Official title | A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) |
| Acronym | ARIEL2 |
| Lead sponsor | pharmaand GmbH, Industry |
| Collaborators | Foundation Medicine Industry Myriad Genetics, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Oral rucaparib |
| Enrollment | 491 |
| Start date | Oct 30, 2013 |
| Primary completion | Nov 5, 2019 |
| Completion | Sep 28, 2021 |
| First posted | Jul 3, 2013 |
| Last update posted | Jun 12, 2023 |
| Countries | Australia, Canada, France, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: